As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
11 Analysts have issued a Assembly Biosciences, Inc. forecast:
11 Analysts have issued a Assembly Biosciences, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 33 33 |
55%
55%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -43 -43 |
14%
14%
|
|
| EBIT (Operating Income) EBIT | -44 -44 |
14%
14%
|
|
| Net Profit | -39 -39 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Jason Okazaki |
| Employees | 73 |
| Founded | 2005 |
| Website | www.assemblybio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


